Get App
Download App Scanner
Scan to Download
Advertisement
This Article is From Sep 08, 2021

India Pharma Market Growth At 18% In August Led By Recovery In Volumes, Non-Covid Drugs: Anand Rathi

India Pharma Market Growth At 18% In August Led By Recovery In Volumes, Non-Covid Drugs: Anand Rathi
Bottles of pills as they are filled  at a facility. (Photographer: Akos Stiller/Bloomberg)
STOCKS IN THIS STORY
Ajanta Pharma Ltd.
--
Ipca Laboratories Ltd.
--
Natco Pharma Ltd.
--
Alembic Pharmaceuticals Ltd.
--
FDC Ltd.
--
JB Chemicals & Pharmaceuticals Ltd.
--
Cipla Ltd.
--
Pfizer Ltd.
--
Sanofi Consumer Healthcare India Ltd
--
Eris Lifesciences Ltd.
--
Lupin Ltd.
--
Sun Pharmaceutical Industries Ltd.
--
Glaxosmithkline Pharmaceuticals Ltd.
--
Biocon Ltd.
--
Alembic Pharmaceuticals Ltd.
--
Indoco Remedies Ltd.
--
Abbott India Ltd.
--
Glenmark Pharmaceuticals Ltd.
--
Astrazeneca Pharma India Ltd.
--
Torrent Pharmaceuticals Ltd.
--

BQ Blue's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BloombergQuint's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Anand Rathi Report

Driven by a volume bounce-back and recovery in sales of non-Covid-19 sales, the India Pharma Market grew 17.7% in August.

The non-Covid-19 drug range, which makes up 63% of the market, is now growing in mid-teens, while the Covid-19 portfolio still continues to grow faster.

In August, volumes aided 9% growth while price growth was 5.9%, and 2.9% from launches.

Acute therapy sales grew at a strong 24.5%, while chronic and sub-chronic therapies grew 10.1% and 14.7% respectively.

Click on the attachment to read the full report:

Anand Rathi IPM August.pdf
VIEW DOCUMENT

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

To continue reading this story
You must be an existing Premium User

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search